PepGen Inc. (NASDAQ:PEPG – Get Free Report) was the target of a large increase in short interest during the month of February. As of February 15th, there was short interest totalling 852,600 shares, an increase of 26.2% from the January 31st total of 675,600 shares. Based on an average trading volume of 2,050,000 shares, the short-interest ratio is currently 0.4 days. Approximately 3.1% of the company’s shares are short sold.
Analyst Upgrades and Downgrades
A number of brokerages recently issued reports on PEPG. HC Wainwright restated a “buy” rating and set a $16.00 price target on shares of PepGen in a report on Monday, February 24th. Bank of America downgraded PepGen from a “neutral” rating to an “underperform” rating and set a $3.00 target price for the company. in a report on Monday, December 16th. Finally, Wedbush reduced their price objective on shares of PepGen from $19.00 to $12.00 and set an “outperform” rating on the stock in a research report on Friday, November 8th.
Get Our Latest Research Report on PEPG
PepGen Trading Down 2.9 %
PepGen (NASDAQ:PEPG – Get Free Report) last posted its quarterly earnings results on Monday, February 24th. The company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($0.81) by $0.13. As a group, equities analysts expect that PepGen will post -2.73 EPS for the current fiscal year.
Institutional Trading of PepGen
Institutional investors have recently added to or reduced their stakes in the business. RTW Investments LP bought a new stake in PepGen in the 4th quarter worth approximately $12,102,000. Janus Henderson Group PLC boosted its position in PepGen by 331.2% in the third quarter. Janus Henderson Group PLC now owns 2,336,516 shares of the company’s stock worth $20,012,000 after purchasing an additional 1,794,641 shares during the last quarter. Suvretta Capital Management LLC increased its position in shares of PepGen by 9.2% during the 3rd quarter. Suvretta Capital Management LLC now owns 1,660,932 shares of the company’s stock valued at $14,201,000 after purchasing an additional 140,000 shares during the last quarter. Northern Trust Corp boosted its holdings in shares of PepGen by 5.4% in the fourth quarter. Northern Trust Corp now owns 157,038 shares of the company’s stock worth $595,000 after buying an additional 7,984 shares during the last quarter. Finally, Millennium Management LLC increased its holdings in PepGen by 1,033.2% during the fourth quarter. Millennium Management LLC now owns 156,636 shares of the company’s stock valued at $594,000 after buying an additional 142,814 shares during the last quarter. 58.01% of the stock is currently owned by hedge funds and other institutional investors.
PepGen Company Profile
PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.
Featured Stories
- Five stocks we like better than PepGen
- What is a Stock Market Index and How Do You Use Them?
- These 3 Iconic Brands Just Announced Bigger Dividend Payouts
- Stock Sentiment Analysis: How it Works
- Zscaler: Bullish Pressure Builds, Rapid Price Increase Expected
- 3 Monster Growth Stocks to Buy Now
- 4 EV Stocks Facing Uncertainty—Which Ones Will Survive?
Receive News & Ratings for PepGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PepGen and related companies with MarketBeat.com's FREE daily email newsletter.